Recruiting PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT06243393

Sacituzumab Govitecan in Metastatic Colorectal Cancer (TROPHIT1)

A Randomized, Open Label, Multicenter Phase II/III Trial of Sacituzumab Govitecan Compared to Standard of Care in Metastatic, Refractory Colorectal Cancer Patients

Sponsor: University Hospital Heidelberg

Conditions Metastatic Colorectal Cancer

Interventions Physicians Choice (PhC). Sacituzumab Govitecan (SG)

Updated 5 times since 2024 Last updated: Jul 8, 2024 Started: Apr 19, 2024 Primary completion: Aug 1, 2028 Completion: Feb 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Metastatic Colorectal Cancer and is currently actively recruiting participants. University Hospital Heidelberg leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2/PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3
Mar 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Heidelberg

Data source: University Hospital Heidelberg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany